$14.7B bid to boost immunology

Posted 3 June 2025 PM

Sanofi has found a use for a large chunk of the cash it received from selling off consumer healthcare business Opella, signing a huge deal to expand its immunology portfolio.

The French pharma has tendered an offer totalling $14.65 billion (US$9.5 billion) for Blueprint Medicines Corporation, a US publicly traded biopharmaceutical company specialising in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. It's the majority of the $17 billion Sanofi pocketed selling half of consumer healthcare spin-off Opella to private equity last month.

To see the whole article, please login